Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly Whomps Novo Nordisk
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s drug.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters.
Lilly’s Zepbound tops Novo Nordisk’s Wegovy in head-to-head obesity study
The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.
Eli Lilly's Zepbound defeats Novo Nordisk's Wegovy in head-to-head weight loss trial
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Zepbound Tops Wegovy for Weight Loss in Eli Lilly Study
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nor
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
In new trial, Zepbound bests Wegovy for weight loss
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Study participants treated with Zepbound lost 20% of their body weight. A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight in less time.
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
JD Supra
2d
Novo Nordisk Urges FDA to Ban Compounded Semaglutide – What Weight-Loss Clinic Owners Need to Know
Novo Nordisk, the manufacturer of Ozempic and Wegovy, has petitioned the Food and Drug Administration (FDA) to add ...
FiercePharma
2d
AbbVie’s Skyrizi retains DTC spending crown, as Novo’s Wegovy sees first entry
That’s according to the latest data from real-time ad trackers iSpot.TV. Their analysts found AbbVie’s immunology drug duo ...
STAT
4d
Pharmalittle: We’re reading about a Zepbound-Wegovy faceoff, compounders slamming Novo, and more
Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...
6d
on MSN
Exclusive-Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...
GlobalData on MSN
10d
Health Canada approves Novo Nordisk’s Wegovy to cut heart attacks
Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, to reduce the risk of non-fatal myocardial ...
globalconstructionreview
4d
Wegovy-maker Novo Nordisk to build €390m quality control centre
Novo Nordisk, the Danish company that makes diabetes drug Ozempic and obesity treatment Wegovy, has begun work on a 5.3ha ...
2d
Novo Holdings' $16.5 Billion Catalent Buy Wins EU Antitrust Approval
BRUSSELS (Reuters) -Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S.
4d
on MSN
Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 million
By Gnaneshwar Rajan and Maggie Fick (Reuters) -U.S.-based vaccine maker Novavax said on Wednesday it will sell its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback